Thrombolytic and anticoagulant therapy for acute submassive pulmonary embolism

Fei,Jianwen; Tang,Yan; Wu,Jinxiang; Kang,Lijun; Zhao,Jiping; Dai,Hong; Bi,Wenxiang; Wang,Junfei; Liu,Fen; Liu,Wen; Yang,Meng; Dong,Liang

doi:10.3892/etm.2013.1355

Thrombolytic and anticoagulant therapy for acute submassive pulmonary embolism

Authors:
- Jianwen Fei
- Yan Tang
- Jinxiang Wu
- Lijun Kang
- Jiping Zhao
- Hong Dai
- Wenxiang Bi
- Junfei Wang
- Fen Liu
- Wen Liu
- Meng Yang
- Liang Dong
View Affiliations

Affiliations: Department of Pulmonary Medicine, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Department of Pulmonary Medicine, Yantai Shan Hospital, Yantai, Shandong 264001, P.R. China, Institute of Biochemistry and Molecular Biology, School of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: October 22, 2013 https://doi.org/10.3892/etm.2013.1355
Pages: 103-108

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study aimed to compare the efficacy and safety of thrombolytic and anticoagulant therapy for acute submassive pulmonary embolism (PE). A retrospective evaluation was performed on 25 consecutive inpatients with acute submassive PE treated by thrombolytic therapy and 25 earlier consecutive inpatients with acute submassive PE treated by anticoagulant therapy. No statistically significant difference in clinical curative effect was identified between the thrombolysis and anticoagulation groups (P>0.05). Following 24 h of therapy, the improvement rates of dyspnea and revascularization in the thrombolysis group achieved statistical significance compared with those of the anticoagulation group (P<0.01 for each). The PO2 level of the thrombolysis group (81.18±5.66 mmHg) was notably higher than that of the anticoagulation group and the difference was statistically significant (P<0.01). The pulmonary arterial pressures of the thrombolysis group (51.21±6.86 mmHg) were significantly lower than those of the anticoagulation group (60.64±5.17 mmHg) (P<0.01). Furthermore, the difference between the hemorrhage rates of the two groups was statistically significant (P<0.05). Thrombolysis was shown to rapidly relieve dyspnea, reduce pulmonary arterial pressure and revascularize the embolized blood vessels. However, the hemorrhage rate of the thrombolysis group was higher than that of the anticoagulation group. The overall efficacies and fatality rates of the thrombolysis and anticoagulation groups were similar.

View Figures

View References

1	Heit JA, Melton LR III, Lohse CM, et al: Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc. 76:1102–1110. 2001. View Article : Google Scholar : PubMed/NCBI
2	Ryan MG, Westrich GH, Potter HG, et al: Effect of mechanical compression on the prevalence of proximal deep venous thrombosis as assessed by magnetic resonance venography. J Bone Joint Surg Am. 84-A:1998–2004. 2002.PubMed/NCBI
3	Sanchez O, Planquette B and Meyer G: Update on acute pulmonary embolism. Eur Respir Rev. 18:137–147. 2009. View Article : Google Scholar : PubMed/NCBI
4	Tapson VF, Carroll BA, Davidson BL, et al; American Thoracic Society. The diagnostic approach to acute venous thromboembolism. Clinical practice guideline. Am J Respir Crit Care Med. 160:1043–1066. 1999. View Article : Google Scholar : PubMed/NCBI
5	American College of Emergency Physicians Clinical Policies Committee and Clinical Policies Committee Subcommittee on Suspected Pulmonary Embolism. Clinical policy: critical issues in the evaluation and management of adult patients presenting with suspected pulmonary embolism. Ann Emerg Med. 41:257–270. 2003. View Article : Google Scholar : PubMed/NCBI
6	Torbicki A, Perrier A, Konstantinides S, et al; ESC Committee for Practice Guidelines (CPG). Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 29:2276–2315. 2008. View Article : Google Scholar : PubMed/NCBI
7	Tapson VF: Treatment of pulmonary embolism: anticoagulation, thrombolytic therapy, and complications of therapy. Crit Care Clin. 27:825–839. 2011. View Article : Google Scholar : PubMed/NCBI
8	Gould MK, Dembitzer AD, Doyle RL, Hastie TJ and Garber AM: Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med. 130:800–809. 1999. View Article : Google Scholar
9	Hirsh J, Hale GS, McDonald IG, McCarthy RA and Pitt A: Streptokinase therapy in acute major pulmonary embolism: effectiveness and problems. Br Med J. 4:729–734. 1968. View Article : Google Scholar : PubMed/NCBI
10	Ly B, Arnesen H, Eie H and Hol R: A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand. 203:465–470. 1978. View Article : Google Scholar : PubMed/NCBI
11	Marini C, Di Ricco G, Rossi G, Rindi M, Palla R and Giuntini C: Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial. Respiration. 54:162–173. 1988. View Article : Google Scholar : PubMed/NCBI
12	Jerjes-Sanchez C, Ramirez-Rivera A, de Lourdes García M, et al: Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis. 2:227–229. 1995. View Article : Google Scholar : PubMed/NCBI
13	Konstantinides S, Geibel A, Heusel G, et al; Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 347:1143–1150. 2002. View Article : Google Scholar : PubMed/NCBI
14	Wan S, Quinlan DJ, Agnelli G and Eikelboom JW: Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation. 110:744–749. 2004. View Article : Google Scholar : PubMed/NCBI
15	Dalen JE: The uncertain role of thrombolytic therapy in the treatment of pulmonary embolism. Arch Intern Med. 162:2521–2523. 2002. View Article : Google Scholar : PubMed/NCBI
16	Kearon C, Kahn SR, Agnelli G, et al; American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 133(6 Suppl): 454S–545S. 2008. View Article : Google Scholar
17	Büller HR: Treatment of symptomatic venous thromboembolism: improving outcomes. Semin Thromb Hemost. 28(Suppl 2): 41–48. 2002.PubMed/NCBI
18	Hyers TM, Agnelli G, Hull RD, et al: Antithrombotic therapy for venous thromboembolic disease. Chest. 119(1 Suppl): 176S–193S. 2001. View Article : Google Scholar : PubMed/NCBI
19	Becattini C, Agnelli G, Salvi A, et al; TIPES Study Group. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res. 125:e82–e86. 2010. View Article : Google Scholar : PubMed/NCBI
20	Fiumara K, Kucher N, Fanikos J and Goldhaber SZ: Predictors of major hemorrhage following fibrinolysis for acute pulmonary embolism. Am J Cardiol. 97:127–129. 2006. View Article : Google Scholar : PubMed/NCBI
21	Kanter DS, Mikkola KM, Patel SR, Parker JA and Goldhaber SZ: Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest. 111:1241–1245. 1997. View Article : Google Scholar : PubMed/NCBI
22	van Belle A, Büller HR, Huisman MV, et al; Christopher Study Investigators. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA. 295:172–179. 2006.
23	Meyer G, Sors H, Charbonnier B, et al: Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. J Am Coll Cardiol. 19:239–245. 1992. View Article : Google Scholar
24	Sakuma M, Konno Y and Shirato K: Increasing mortality from pulmonary embolism in Japan, 1951–2000. Circ J. 66:1144–1149. 2002.PubMed/NCBI
25	Büller HR, Davidson BL, Decousus H, et al; Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 349:1695–1702. 2003.PubMed/NCBI
26	Quinlan DJ, McQuillan A and Eikelboom JW: Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med. 140:175–183. 2004. View Article : Google Scholar